Literature DB >> 20858962

Low serum progranulin predicts the presence of mutations: a prospective study.

Emma C Schofield1, Glenda M Halliday, John Kwok, Clement Loy, Kay L Double, John R Hodges.   

Abstract

Serum progranulin is decreased in frontotemporal dementia (FTD) patients with progranulin gene (PGRN) mutations. We investigate the utility of prospective serum screening as a surrogate diagnostic marker for progranulin mutations. A commercial ELISA was used to measure progranulin protein concentration in serum from 63 FTD patients and 32 normal controls, and DNA screening then performed. Four patients (2/17 behavioral variant, 2/8 corticobasal syndrome) had abnormally low progranulin levels with PGRN mutations confirmed on DNA testing. Surprisingly, elevated levels were found in 6/16 patients with progressive non-fluent aphasia, the significance of which is unclear. Serum testing is an accurate and cost effective means of predicting PGRN mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858962     DOI: 10.3233/JAD-2010-101032

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  23 in total

1.  Alzheimer's disease clinical trials: changing the paradigm.

Authors:  Jeffrey L Cummings
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

2.  Parkinsonism and frontotemporal dementia: the clinical overlap.

Authors:  Alberto J Espay; Irene Litvan
Journal:  J Mol Neurosci       Date:  2011-09-03       Impact factor: 3.444

Review 3.  Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.

Authors:  Yazhou Cui; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2019-01-30       Impact factor: 7.638

4.  Fluid Biomarkers of Frontotemporal Lobar Degeneration.

Authors:  Emma L van der Ende; John C van Swieten
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Progranulin genetic screening in frontotemporal lobar degeneration patients from central Italy.

Authors:  Silvia Bagnoli; Irene Piaceri; Andrea Tedde; Silvia Piacentini; Serena Nannucci; Laura Bracco; Sandro Sorbi; Benedetta Nacmias
Journal:  Cell Mol Neurobiol       Date:  2011-07-29       Impact factor: 5.046

6.  Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma.

Authors:  Minerva M Carrasquillo; Alexandra M Nicholson; NiCole Finch; J Raphael Gibbs; Matt Baker; Nicola J Rutherford; Talisha A Hunter; Mariely DeJesus-Hernandez; Gina D Bisceglio; Ian R Mackenzie; Andrew Singleton; Mark R Cookson; Julia E Crook; Allissa Dillman; Dena Hernandez; Ronald C Petersen; Neill R Graff-Radford; Steven G Younkin; Rosa Rademakers
Journal:  Am J Hum Genet       Date:  2010-11-18       Impact factor: 11.025

Review 7.  Frontotemporal dementia: from Mendelian genetics towards genome wide association studies.

Authors:  Raffaele Ferrari; John Hardy; Parastoo Momeni
Journal:  J Mol Neurosci       Date:  2011-09-06       Impact factor: 3.444

8.  Circulating progranulin as a biomarker for neurodegenerative diseases.

Authors:  Roberta Ghidoni; Anna Paterlini; Luisa Benussi
Journal:  Am J Neurodegener Dis       Date:  2012-08-02

9.  Progranulin protein levels are differently regulated in plasma and CSF.

Authors:  Alexandra M Nicholson; NiCole A Finch; Colleen S Thomas; Aleksandra Wojtas; Nicola J Rutherford; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; David S Knopman; Ronald C Petersen; Rosa Rademakers
Journal:  Neurology       Date:  2014-04-25       Impact factor: 9.910

Review 10.  Parkinsonian syndrome in familial frontotemporal dementia.

Authors:  Joanna Siuda; Shinsuke Fujioka; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2014-06-13       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.